Group 2 innate
lymphoid cells mediate ozone-induced airway inflammation and hyperresponsiveness in mice.
The migration-inhibition of
lymphoid cells observed in the present study is similar to that of exudates cells obtained from hypersensitive guinea pigs in the presence (in the medium) of specific antigen.
With respect to commonly observed HCV reinfection of liver allografts in patients with end-stage diseases caused by chronic hepatitis C, migration of
lymphoid cells, including those carrying not readily detectable quantities of replicating virus, may constitute a main mechanism by which the transplanted liver becomes infected.
These cells named innate
lymphoid cells group 2 (ILC2s) cells are rare, systematically dispersed and exist in humans.
A through C, The atypical
lymphoid cells are positive for annexin A1 (partial) (A), DBA44 (B), and BCL1 (partial) (C) (original magnification X400 [A]; original magnification X200 [B]; original magnification X200 [C]).
2013) Cutaneous immunosurveillance and regulation of inflammation by group 2 innate
lymphoid cells.
Group 2 innate
lymphoid cells (ILC2s) in peripheral blood have recently been described in the initiation and maintenance of human allergic diseases, such as AR, atopic dermatitis, and allergic asthma.
Another important advance was the discovery of type 2 innate
lymphoid cells (ILC2s), "first responders" in the skin.
2 A: Dermis showing sheets of atypical
lymphoid cells of intermediate to large size with brisk mitotic activity (hematoxylin & eosin staining [H&E] x400); B: Sheets of atypical
lymphoid cells replacing testicular parenchyma showing frequent mitoses (H&E x400), inset--residual entrapped seminiferous tubules in the tumour (H&E x200); C: Tumour cells showing positivity for leukocyte common antigen (x400); D: Tumour cells showing positivity for CD20 (x400).
White matter revealed infiltration by large neoplastic
lymphoid cells with vesicular nuclei, prominent eosinophilic nucleoli, diffusely distributed (Fig 1).
Anaplastic large cell lymphoma (ALCL) was first described in 1985 by Stein et al as a unique lymphoma characterized by large pleomorphic
lymphoid cells, often with horseshoe-shaped nuclei and a sinusoidal growth pattern1.
The product is a once-daily oral anti-Th2 therapy and has been indicated to block the recruitment and activation of Th2 lymphocytes, type 2 innate
lymphoid cells, eosinophils and basophils and is presently in a Phase 2 study in patients with atopic dermatitis in leading centres throughout Europe.
